VAR2CSA Immunogen Segmentation for Placental Malaria Vaccine
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The development of effective vaccines and therapeutics against placental malaria caused by P. falciparum is hindered by the large size and polymorphic nature of the VAR2CSA protein, particularly due to challenges in producing the VAR2CSA protein for scientific study and the need for a strain-transcending solution, as well as a lack of understanding about its specific recognition mechanism for chondroitin sulfate A binding.
Innovation Solution
The development of immunogen polypeptides comprising all or portions of the major and minor CSA binding channels, the arm segment, or combinations thereof, which can be used to create pharmaceutical compositions for vaccination and treatment, including mRNA-based approaches to produce these polypeptides in cells, to target malaria and cancer cells expressing chondroitin sulfate A.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the complete VAR2CSA protein is used as an immunogen, then comprehensive immune coverage is achieved, but production difficulty and cost increase significantly
Solution Approach 1:
The patent divides the large VAR2CSA protein into smaller functional segments: the core domain containing CSA binding channels (DBL1X, DBL2X, DBL4ε, ID2, ID3 domains) and the arm segment (DBL5ε, DBL6ε domains). This segmentation allows production of manageable protein fragments that retain specific functions, resolving the contradiction between comprehensive coverage and manufacturing ease.
Solution Approach 2:
The patent extracts and isolates the critical functional elements of VAR2CSA - specifically the CSA binding channels within the core domain - to create immunogens that focus on the most immunogenic and functionally important regions. This extraction approach produces smaller, more manufacturable proteins that capture essential immune responses.
2Adaptability or versatility
If diverse VAR2CSA variants from multiple strains are included, then strain-transcending protection is achieved, but protein production complexity increases
Solution Approach 1:
The patent identifies and utilizes highly conserved regions within the VAR2CSA core domain that are present across multiple P. falciparum strains. By focusing on these universal elements - particularly the CSA binding channels - the immunogen provides strain-transcending protection without requiring production of multiple strain-specific variants, thus reducing production complexity while maintaining versatility.
Solution Approach 2:
The patent applies local quality by concentrating immunogenic elements from diverse strains into specific conserved regions of the core domain, while allowing variability in less critical regions. This approach enables strain-transcending protection through targeted conserved epitopes without the complexity of incorporating entire diverse protein sequences.
3Loss of information
If the full-length VAR2CSA protein is produced, then complete structural information is obtained, but production yield and purity decrease
Solution Approach 1:
The patent segments the full-length VAR2CSA protein into the core domain and arm segment, allowing independent production and characterization of each portion. This segmentation increases production yield and purity for each fragment while collectively providing comprehensive structural information about the complete protein through assembly of the parts.
Data Source
AI summary
The disclosure provides immunogen polypeptides comprising fragments of VAR2CSA protein expressed by P. falciparum. Aspects of the disclosed immunogen polypeptides comprise all or portions of the CSA binding regions of VAR2CSA as identified by a structural study of VAR2CSA conducted by the inventors. Also provided are compositions comprising such immunogen polypeptides, and methods of using the immunogen polypeptides for vaccination and treatment of disease.